Filtered By:
Specialty: Hematology
Source: Thrombosis and Haemostasis
This page shows you your search results in order of relevance. This is page number 17.
Order by Relevance | Date
Total 528 results found since Jan 2013.
Atrial fibrillation, liver cirrhosis, thrombosis, and bleeding: A Danish population-based cohort study
CONCLUSION: In patients with AFF, liver cirrhosis was associated with an elevated risk of ischemic stroke, venous thromboembolism, and all evaluated bleeding complications.PMID:35229067 | PMC:PMC8867136 | DOI:10.1002/rth2.12668
Source: Thrombosis and Haemostasis - March 1, 2022 Category: Hematology Authors: Emil B Riahi Kasper Adelborg Lars Pedersen S øren R Kristensen Anette T Hansen Henrik T S ørensen Source Type: research
Dilemmas in hematology: consults in patients with arterial thrombosis
J Thromb Haemost. 2023 Jan 10:S1538-7836(23)00030-2. doi: 10.1016/j.jtha.2023.01.002. Online ahead of print.ABSTRACTArterial thrombotic events, particularly ischemic stroke and myocardial infarction, are common, and mostly occur due to atherosclerotic disease or arrhythmias. The diagnosis and management of the majority of such events occurs without the involvement of a hematologist, following established guidelines or pathways. In this review, we discuss 3 scenarios in which optimal management is less certain. These scenarios concern patients with a left ventricular thrombus, in whom the duration and choice of anticoagulan...
Source: Thrombosis and Haemostasis - January 25, 2023 Category: Hematology Authors: Dawn Swan Jean M Connors Jecko Thachil Source Type: research
Prevalence of selected bleeding and thrombotic events in persons with hemophilia versus the general population: A scoping review
Res Pract Thromb Haemost. 2022 Dec 9;7(1):100007. doi: 10.1016/j.rpth.2022.100007. eCollection 2023 Jan.ABSTRACTLife expectancy for persons with hemophilia has increased over recent decades due to advances in treatment practice and patient care. Those with hemophilia are now more likely to be affected by conditions associated with aging, such as myocardial infarction, hemorrhagic/ischemic stroke, deep vein thrombosis, pulmonary embolism, and intracranial hemorrhage. Here, we describe the results of a literature search designed to summarize current data on the prevalence of the above selected bleeding and thrombotic events ...
Source: Thrombosis and Haemostasis - March 9, 2023 Category: Hematology Authors: Amy D Shapiro Brandon M Hardesty Flora Peyvandi Alfonso Iorio Source Type: research
Atrial fibrillation in cancer: thromboembolism and bleeding in daily practice
CONCLUSION: Patients with AF and active cancer experience high rates of thromboembolic and bleeding complications, underlying the complexity of anticoagulant management in these patients. Our data suggest that the presence of cancer is an important factor in determining the indication for anticoagulants in patients with a low CHA2DS2-VASc score.PMID:37063771 | PMC:PMC10099322 | DOI:10.1016/j.rpth.2023.100096
Source: Thrombosis and Haemostasis - April 17, 2023 Category: Hematology Authors: Gordon Chu Jaap Seelig Suzanne C Cannegieter Hans Gelderblom Marcel M C Hovens Menno V Huisman Tom van der Hulle Serge A Trines Andr é J Vlot Henri H Versteeg Martin E W Hemels Frederikus A Klok Source Type: research
Visit-to-Visit Heart Rate Variability in the Prediction of Clinical Outcomes of Patients with Atrial Fibrillation
CONCLUSION: VVV-HR is an independent predictor for adverse clinical outcomes in patients with AF. A J-curve appearance was demonstrated for the effect of VVV-HR on all-cause death.PMID:37116533 | DOI:10.1055/s-0043-1768580
Source: Thrombosis and Haemostasis - April 28, 2023 Category: Hematology Authors: Rungroj Krittayaphong Warangkna Boonyapisit Poom Sairat Gregory Y H Lip Source Type: research
Mobile Health-Technology-Integrated Care for Atrial Fibrillation: A Win Ratio Analysis from the mAFA-II Randomized Clinical Trial
CONCLUSIONS: In this posthoc WR analysis of the mAFA-II trial, a mHealth-technology-implemented integrated care approach was effective in reducing the risk of the primary composite outcome of all-cause death, ischemic stroke or thromboembolism, and rehospitalization, even when prioritizing fatal events.PMID:37247623 | DOI:10.1055/s-0043-1769612
Source: Thrombosis and Haemostasis - May 29, 2023 Category: Hematology Authors: Giulio Francesco Romiti Yutao Guo Bernadette Corica Marco Proietti Hui Zhang Gregory Y H Lip mAF-App II trial investigators Source Type: research
The Impact of Polypharmacy on the Effectiveness and Safety of Non-vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation
CONCLUSION: Polypharmacy was associated with increased thromboembolic, bleeding, and mortality risks in AF patients. NOACs had better benefit-risk profiles than VKAs in patients with polypharmacy.PMID:37369234 | DOI:10.1055/s-0043-1769735
Source: Thrombosis and Haemostasis - June 27, 2023 Category: Hematology Authors: Maxim Grymonprez Mirko Petrovic Tine L De Backer Stephane Steurbaut Lies Lahousse Source Type: research
Patient outcomes using the European label for dabigatran. A post-hoc analysis from the RE-LY database.
In conclusion, this post-hoc simulation of dabigatran usage based on RE-LY trial dataset indicates that "EU label simulated dabigatran treatment" may be associated with superior efficacy and safety compared to warfarin, and are in support of the EU label and the 2012 European Society of Cardiology AF guideline recommendations. Thus, adherence to European label/guideline use results in a clinically relevant benefit for dabigatran over warfarin, for both efficacy and safety.
PMID: 24326736 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - December 11, 2013 Category: Hematology Authors: Lip GY, Clemens A, Noack H, Ferreira J, Connolly SJ, Yusuf S Tags: Thromb Haemost Source Type: research
